Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideABTAbbott Laboratories
FinDog View：Neutral
JNJJohnson & Johnson
FinDog View：Bullish
| Metric | ABT | JNJ |
|---|
| Close | 102.36 | 267.28 |
| Market Cap | $177B | $644B |
| 1M | −7.26% | +1.87% |
| P/E (TTM) | 33.2 | 30.6 |
| Forward P/E | 18.1 | 20.7 |
| P/E 5-Yr Percentile | 66 | 90 |
| P/S | 3.9 | 6.6 |
| P/B | 3.5 | 7.6 |
| Dividend Yield | 1.98% | 3.12% |
| Latest Quarter Revenue | $11.2B | $25.3B |
| Revenue YoY | +7.8% | +6.6% |
| Gross Margin | 56.2% | 68.2% |
| Latest Quarter EPS | 0.61 | 2.27 |
| Avg Post-Earnings Move | ±1.6% | ±0.6% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | 2.81% | 1.25% |
| 90-Day Net Insider Buying | −$46.7M | −$67.8M |
ABT · Revenue, Last 8 Quarters ($B)
JNJ · Revenue, Last 8 Quarters ($B)
